Baricitinib 2 MG

DRUG6 trials

Sponsors

Peking Union Medical College Hospital, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Assiut University, Peking University People's Hospital, ANRS, Emerging Infectious Diseases

Conditions

HIV-1-infectionImmune ThrombocytopeniaLupus or SLENephritisRheumatoid ArthritisSjogren's Syndrome

Phase 1

A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

CompletedNCT04916756

Peking Union Medical College HospitalSjogren's Syndrome

Start: 2020-01-16End: 2021-03-25Updated: 2021-06-30

Phase 2

Use of Baricitenib to Maintain of Remission

Assiut UniversityLupus or SLE, Nephritis

Start: 2022-06-01End: 2023-08-01Target: 80Updated: 2023-01-17

Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia

Peking University People's HospitalImmune Thrombocytopenia

Start: 2023-07-07End: 2025-06-30Target: 132Updated: 2023-07-12

Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

Not yet recruitingNCT07081763

ANRS, Emerging Infectious DiseasesHIV-1-infection

Start: 2026-05-31End: 2030-11-30Target: 191Updated: 2025-07-23

Phase 4

Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

CompletedNCT05660655

Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshRheumatoid Arthritis

Start: 2022-10-01End: 2023-09-30Updated: 2023-11-18

Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial

Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshRheumatoid Arthritis

Start: 2023-04-01End: 2024-03-31Target: 132Updated: 2023-04-25

Related Papers

Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country

BMC Rheumatology2026-03-30